Fingolimod Lauryl: uses, dosing, side effects & brands

Q: What is fingolimod lauryl?

Tascenso ODT (Fingolimod Lauryl Sulfate) is a medication used to treat Relapsing-Remitting Multiple Sclerosis.

Q: How long does fingolimod lauryl stay in your system?

The elimination half-life of fingolimod lauryl is about 6 to 9 days (average apparent terminal half-life) — that is how long the body takes to clear half of a dose. This is the terminal (elimination) half-life, not a distribution phase. Fingolimod is a prodrug-like parent: it is phosphorylated by sphingosine kinase to fingolimod-phosphate, the pharmacologically active moiety. The label says fingolimod-phosphate blood levels decline in parallel with the parent in the terminal phase, "yielding similar half-lives for both" — so the active form does not outlast the parent, but it also does not clear any faster. Because the half-life is measured in days, blood levels take 1 to 2 months of once-daily dosing to reach steady state, and lymphocyte counts typically take 1 to 2 months to return to normal after stopping. Liver impairment: the apparent elimination half-life is unchanged in mild hepatic impairment but is prolonged by about 50% in moderate or severe impairment (Child-Pugh B or C); fingolimod AUC rises 12%/44%/103% in mild/moderate/severe. Kidney impairment: in severe renal impairment there is NO change in apparent elimination half-life (though fingolimod Cmax/AUC rise 32%/43%, and two inactive metabolites, M2 and M3, accumulate 3- and 13-fold). Older adults: the label states no dose adjustment is expected based on the elimination mechanism and population PK, but does not report a separate half-life for this group and notes experience above age 65 is limited. Not a drug-test detection window and not dosing guidance. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

Q: Can you take fingolimod lauryl with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run fingolimod lauryl against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

Q: What forms does fingolimod lauryl come in?

Across the brands we track, fingolimod lauryl is currently marketed as tablet, orally disintegrating, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Q: Is there a generic fingolimod lauryl?

We do not currently list a generic-labelled fingolimod lauryl product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

Fingolimod Lauryl is a medicine sold in the U.S. under one brand, for relapsing-remitting multiple sclerosis. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesUpdated Jul 24, 2026How we research

Key facts

Treats: Relapsing-Remitting Multiple Sclerosis
Available as: Tablet, orally disintegrating
Sold as: Tascenso ODT
Prescription?: Prescription only
Generic available?: Not in our catalog
Half-life: about 6 to 9 days (average apparent terminal half-life)

How fingolimod lauryl is dosed

From the FDA label for Tascenso ODT (application NDA214962). Other fingolimod lauryl products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

Assessments are required prior to initiating TASCENSO ODT ( 2.1 ) Recommended dosage for adults and pediatric patients (10 years of age and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food. ( 2.2 , 2.3 ) Recommended dosage for pediatric patients (10 years of age and older) weighing less than or equal to 40 kg: 0.25 mg orally once daily, with or without food ( 2.2 , 2.3 ). Administer TASCENSO ODT with or without water. Place tablet directly on the tongue and allow it to dissolve before swallowing. ( 2.2 ) First-Dose Monitoring (including reinitiation after discontinuation greater than 14 days and dose increases): Observe all patients for bradycardia for at least 6 hours; monitor pulse and blood pressure hourly. Electrocardiograms (ECGs) prior to dosing and at end of observation period required. ( 2.4 ) Monitor until resolution if heart rate < 45 beats per minute (bpm) in adults, < 55 bpm in patients aged 12 years and above, or < 60 bpm in pediatric patients aged 10 to below 12 years, atrioventricular (AV) block, or if lowest postdose heart rate is at the end of the observation period. ( 2.4 ) Monitor symptomatic bradycardia with ECG until resolved. Continue overnight if intervention is required; repeat first-dose monitoring for second dose. ( 2.4 ) Observe patients overnight if at higher risk of symptomatic bradycardia, heart block, prolonged QTc…

Fingolimod Lauryl side effects

The following serious adverse reactions are described elsewhere in labeling: Bradyarrhythmia and Atrioventricular Blocks [see Warnings and Precautions (5.1) ] Infections [see Warnings and Precautions (5.2) ] Progressive Multifocal Leukoencephalopathy [see Warnings and Precautions (5.3) ] Macular Edema [see Warnings and Precautions (5.4) ] Liver Injury [see Warnings and Precautions (5.5) ] Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.6) ] Respiratory Effects [see Warnings and Precautions (5.7) ] Fetal Risk [see Warnings and Precautions (5.8) ] Severe Increase in Disability After Stopping TASCENSO ODT [see Warnings and Precautions (5.9) ] Tumefactive Multiple Sclerosis [see Warnings and Precautions (5.10) ] Increased Blood Pressure [see Warnings and Precautions (5.11) ] Malignancies [see Warnings and Precautions (5.12) ] Immune System Effects Following TASCENSO ODT Discontinuation [see Warnings and Precautions (5.13) ] Hypersensitivity Reactions [see Warnings and Precautions (5.14) ] Most common adverse reactions (incidence ≥ 10% and greater than placebo): Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals Ltd at 1-888-533-1625 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical…

Who shouldn’t take fingolimod lauryl

TASCENSO ODT is contraindicated in patients who have: In the last 6 months experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization or Class III/IV heart failure. A history or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker [see Warnings and Precautions (5.1) ] A baseline QTc interval ≥ 500 msec Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs Had a hypersensitivity reaction to fingolimod or any of the excipients in TASCENSO ODT. Observed reactions include rash, urticaria, and angioedema [see Warnings and Precautions (5.14) ]. Concomitant use with other products containing fingolimod Recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure with hospitalization, or Class III/IV heart failure. ( 4 ) History of Mobitz Type II 2 nd degree or 3 rd degree AV block or sick sinus syndrome, unless patient has a pacemaker. ( 4 ) Baseline QTc interval ≥ 500 msec. ( 4 ) Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs. ( 4 ) Hypersensitivity to fingolimod or its excipients. ( 4 ) Concomitant use with other products containing fingolimod. ( 4 )

Fingolimod Lauryl drug interactions

Systemic Ketoconazole : Monitor during concomitant use. ( 7.2 , 12.3 ) Vaccines : Avoid live attenuated vaccines during, and for 2 months after stopping TASCENSO ODT treatment. ( 5.3 , 7.3 ) 7.1 QT Prolonging Drugs TASCENSO ODT has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of TASCENSO ODT treatment results in decreased heart rate and may prolong the QT interval, patients on QT prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility [see Dosage and Administration (2.4) , Warnings and Precautions (5.1) ]. 7.2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole. Patients who use TASCENSO ODT and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is greater. 7.3 Vaccines TASCENSO ODT reduces the immune response to vaccination. Vaccination may be less effective during and for up to 2 months after discontinuation of treatment with TASCENSO ODT [see Clinical Pharmacology (12.2) ] . Avoid the use of live attenuated vaccines during and for 2 months after treatment with TASCENSO ODT because of the risk of infection. It is recommended that pediatric patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating TASCENSO ODT therapy. 7.4 Antineoplastic, Immunosuppressive, or Immune-Modulating Therapies Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with TASCENSO ODT. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating TASCENSO ODT [see Warnings and Precautions (5.2) ]. 7.5 Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with fingolimod in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of TASCENSO ODT treatment may result in an additional decrease in heart rate, concomitant use of these drugs during TASCENSO ODT initiation may be associated with severe bradycardia or heart block. Seek advice from the physician prescribing these drugs regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating TASCENSO ODT. Patients who cannot switch should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2.4) , Warnings and Precautions (5.1) ]. 7.6 Laboratory Test Interaction Because fingolimod reduces blood lymphocyte counts via redistribution in secondary lymphoid organs, peripheral blood lymphocyte counts cannot be utilized to evaluate the lymphocyte subset status of a patient treated with fingolimod. A recent CBC should be available before initiating treatment with TASCENSO ODT.

Every fingolimod lauryl product we track (1)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Only one: Tascenso ODT.

How long fingolimod lauryl stays in your system

The elimination half-life of fingolimod lauryl is about 6 to 9 days (average apparent terminal half-life). This is the terminal (elimination) half-life, not a distribution phase. Fingolimod is a prodrug-like parent: it is phosphorylated by sphingosine kinase to fingolimod-phosphate, the pharmacologically active moiety. The label says fingolimod-phosphate blood levels decline in parallel with the parent in the terminal phase, "yielding similar half-lives for both" — so the active form does not outlast the parent, but it also does not clear any faster. Because the half-life is measured in days, blood levels take 1 to 2 months of once-daily dosing to reach steady state, and lymphocyte counts typically take 1 to 2 months to return to normal after stopping. Liver impairment: the apparent elimination half-life is unchanged in mild hepatic impairment but is prolonged by about 50% in moderate or severe impairment (Child-Pugh B or C); fingolimod AUC rises 12%/44%/103% in mild/moderate/severe. Kidney impairment: in severe renal impairment there is NO change in apparent elimination half-life (though fingolimod Cmax/AUC rise 32%/43%, and two inactive metabolites, M2 and M3, accumulate 3- and 13-fold). Older adults: the label states no dose adjustment is expected based on the elimination mechanism and population PK, but does not report a separate half-life for this group and notes experience above age 65 is limited. Not a drug-test detection window and not dosing guidance.

DailyMed — FINGOLIMOD (fingolimod hydrochloride) capsule, §12.3 Pharmacokinetics ↗

Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.

Related calculators

How long it stays in your system →

Frequently asked questions

What is fingolimod lauryl?

Tascenso ODT (Fingolimod Lauryl Sulfate) is a medication used to treat Relapsing-Remitting Multiple Sclerosis.

How long does fingolimod lauryl stay in your system?

The elimination half-life of fingolimod lauryl is about 6 to 9 days (average apparent terminal half-life) — that is how long the body takes to clear half of a dose. This is the terminal (elimination) half-life, not a distribution phase. Fingolimod is a prodrug-like parent: it is phosphorylated by sphingosine kinase to fingolimod-phosphate, the pharmacologically active moiety. The label says fingolimod-phosphate blood levels decline in parallel with the parent in the terminal phase, "yielding similar half-lives for both" — so the active form does not outlast the parent, but it also does not clear any faster. Because the half-life is measured in days, blood levels take 1 to 2 months of once-daily dosing to reach steady state, and lymphocyte counts typically take 1 to 2 months to return to normal after stopping. Liver impairment: the apparent elimination half-life is unchanged in mild hepatic impairment but is prolonged by about 50% in moderate or severe impairment (Child-Pugh B or C); fingolimod AUC rises 12%/44%/103% in mild/moderate/severe. Kidney impairment: in severe renal impairment there is NO change in apparent elimination half-life (though fingolimod Cmax/AUC rise 32%/43%, and two inactive metabolites, M2 and M3, accumulate 3- and 13-fold). Older adults: the label states no dose adjustment is expected based on the elimination mechanism and population PK, but does not report a separate half-life for this group and notes experience above age 65 is limited. Not a drug-test detection window and not dosing guidance. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

Can you take fingolimod lauryl with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run fingolimod lauryl against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What forms does fingolimod lauryl come in?

Across the brands we track, fingolimod lauryl is currently marketed as tablet, orally disintegrating, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic fingolimod lauryl?

We do not currently list a generic-labelled fingolimod lauryl product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

Cite this page

APA: pharmaranks. (2026, July 24). Fingolimod Lauryl: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/fingolimod-lauryl
MLA: “Fingolimod Lauryl: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/fingolimod-lauryl.

We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.

Read the full FDA label for fingolimod lauryl on DailyMed (NIH) ↗.